De-escalation and Escalation Treatment of Early Breast Cancer—Insights from an Interview with Giuseppe Curigliano at SGBCC 2023

De-escalation and Escalation Treatment of Early Breast Cancer—Insights from an Interview with Giuseppe Curigliano at SGBCC 2023

The 18th St. Gallen International Breast Cancer Conference 2023 held in Vienna provided a platform for experts in the field to share their perspectives on the management of early breast cancer. Among the distinguished attendees was Professor Giuseppe Curigliano from the European Institute of Oncology, IRCCS, Milan, Italy. In the interview by Oncology Frontier, he shed light on the concepts of de-escalation and escalation treatment in early breast cancer cases, addressing the potential benefits and challenges in current and upcoming therapeutic strategies.
SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had  invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.
SGBCC 2023 | Academician  Binghe Xu: Breast Cancer Treatment and Research – An Asian Perspective

SGBCC 2023 | Academician  Binghe Xu: Breast Cancer Treatment and Research – An Asian Perspective

The 18th St.Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Academician Binghe Xu  from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a presentation titled "Breast Cancer Treatment and Research - An Asian Perspective" during the "Session 10: Global Perspective on Breast Cancer Treatment." After his presentation, Academician Binghe Xu  had an interview with Oncology Frontier to discuss related content.
Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the formation of the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years. Oncology Frontier invited Dr. Jian Zhang from Fudan University Affiliated Cancer Hospital to have an in-depth discussion with Dr. Nadia Harbeck from the University of Munich on the topic of whether chemotherapy is needed for patients with low genetic risk but high clinical risk (ER+/HER2-) breast cancer.
Dr. Jia Wang & Dr. William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis

Dr. Jia Wang & Dr. William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis

There is currently a lack of consensus on whether surgical treatment should be performed for patients with stage IV breast cancer at the initial diagnosis. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "Surgery of the primary for stage IV disease" garnered global expert attention. The debate was moderated by  Dr. William Gradishar from Northwestern University Feinberg School of Medicine in the United States, with  Dr. Rajendra Badwe from Tata Research in India and Professor Florian Fitzal from ABCSG-28 Research in Austria presenting opposing views on this issue. "Oncology Frontier" invited  Dr. Jia Wang from the Second Hospital of Dalian Medical University and Dr. William Gradishar from Northwestern University Feinberg School of Medicine to engage in an in-depth discussion on this topic.

Discovery and Verification of HBV Auxiliary Receptor NRP1

Hepatitis B Virus (HBV) infection is one of the main causes of liver diseases, affecting approximately 292 million people worldwide who are chronic carriers of HBV, leading to severe conditions like liver cirrhosis and primary liver cancer. The infection process of HBV relies on the binding of the viral envelope proteins to receptors on the cell surface. Therefore, interfering with the binding of the viral envelope proteins and receptors can be an effective antiviral strategy. During the 15th Chronic Viral Hepatitis Antiviral Treatment Challenges and Hot Topics Academic Conference, held in Chongqing from November 17-19, 2023, and organized by the Chinese Medical Journal Company Ltd., Editorial Office of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology, the Second Affiliated Hospital of Chongqing Medical University, and the Chongqing Medical University Institute of Viral Hepatitis, Dr. Ailong Huang, President of Chongqing Medical University, shared his team's latest research findings on how HBV depends on various receptors and auxiliary receptors to infect cells. This research provides new insights into the mechanism of HBV invasion and the development of novel drugs to block HBV infection.

Interpretation of “Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma”

On December 9-10, 2023, the "Huaxia Shanghai Liver Disease Forum and Shanghai Liver Disease Summit" was successfully held, sponsored by the Huaxia Liver Disease Association, organized by the Shanghai "Liver" Magazine, and co-organized by the Shanghai Medical Association Hepatology Subspecialty Branch, Shanghai Physicians Association Infectious Disease Physicians Branch, Shanghai Infectious Disease Clinical Quality Control Center, and the Long Triangle Representative Office of the China Association of Non-Public Medical Institutions. At the conference, Dr.Xiufeng Liu from the Medical Area of the Qinhuai Hospital of the Eastern Theater General Hospital of the People's Liberation Army provided a detailed interpretation of the "Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma," which was newly issued in China. This journal has invited Dr.Xiufeng Liu to conduct an in-depth interview to introduce the consensus's recommendations regarding first-line and subsequent-line treatment options for liver cancer immunotherapy, as well as the assessment of treatment efficacy and other hot topics. The following content summarizes these insights for readers.